Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 4, 2008, Pages 793-796

  Crespo, Manuel ^a,j   Mira, José A ^b,k   Pineda, Juan A ^b,k   van den Eynde, Eva ^a   Ríos Villegas, María J ^c,k   Collado, Antonio ^d,k   Girón González, José A ^e,k   López Cortés, Luis F ^f,k   González Serrano, Mercedes ^g,k   Rivero, Antonio ^h,k   Merino, Dolores ^i,k   Esteban, Juan I ^a,j  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d HOSPITAL TORRECÁRDENAS   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^h HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

ⁱ HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k Sociedad Andaluza de Enfermedades Infecciosas (SAEI)

more..

Author keywords

HCV non responders; HCV retreatment strategies; HIV co infection

Indexed keywords

ABACAVIR; EMTRICITABINE; ERYTHROPOIETIN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MITOCHONDRIAL TOXICITY; MIXED INFECTION; MONOTHERAPY; NEUROLOGIC DISEASE; NONHUMAN; OBSERVATIONAL STUDY; PATIENT SELECTION; RECURRENCE RISK; RETREATMENT; THROMBOCYTOPENIA; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 52949106160     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn262     Document Type: Article

References (12)

1. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
2. Chung RT, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351 451-9.
3. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. J Am Med Assoc 2004; 292: 2839-48.
4. Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV coinfected patients. Acquir Immune Defic Syndr 2004; 18: F27-36.
5. Crespo M, Sauleda S, Esteban JI et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007; 14: 228-38.
6. Myers RP, Benhamou Y, Bochet M et al. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. Acquir Immune Defic Syndr 2004; 18: 75-9.
7. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF et al. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol 2007; 38: 32-8.
8. Alberti A, Clumeck N, Gerlich W et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-24.
9. Shiffman ML, Di Bisceglie AM, Lindsay KL et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-23.
10. Jacobson IM, Gonzalez SA, Ahmed F et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100: 2453-62.
11. Taliani G, Gemignani G, Ferrari C et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin non-responder patients. Gastroenterology 2006; 130: 1098-106.
12. Shiffman ML, Ghany MG, Morgan TR et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103-12.